Innate Lymphoid Cells in Bladder Cancer: From Mechanisms of Action to Immune Therapies

Onika D.V. Noel, Zaineb Hassouneh, Robert S. Svatek, Neelam Mukherjee

Research output: Contribution to journalReview articlepeer-review


Bladder tumors have a high mutational burden and tend to be responsive to immune therapies; however, response rates remain modest. To date, immunotherapy in bladder cancer has largely focused on enhancing T-cell immune responses in the bladder tumor microenvironment. It is anticipated that other immune cells, including innate lymphoid cells (ILC), which play an important role in bladder oncogenesis and tumor suppression, could be targeted to improve response to existing therapies. ILCs are classified into five groups: natural killer cells, ILC1s, ILC2s, ILC3s, and lymphoid tissue inducer cells. ILCs are pleiotropic and play dual and sometimes paradoxical roles in cancer development and progression. Here, a comprehensive discussion of the current knowledge and recent advancements in understanding the role of ILCs in bladder cancer is provided. We discuss the multifaceted roles that ILCs play in bladder immune surveillance, tumor protection, and immunopathology of bladder cancer. This review provides a rationale for targeting ILCs in bladder cancer, which is relevant for other solid tumors.

Original languageEnglish (US)
Pages (from-to)149-160
Number of pages12
JournalCancer Immunology Research
Issue number2
StatePublished - Feb 1 2024

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Innate Lymphoid Cells in Bladder Cancer: From Mechanisms of Action to Immune Therapies'. Together they form a unique fingerprint.

Cite this